FATE
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Fate Therapeutics, Inc. (FATE) [ST]
www.fatetherapeutics.com ↗▲ 3.33%
prev close
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. The company is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.
Congressional Trades
1
All tracked trades
Members Trading
1
Unique members
Net Activity
-1
0 buys · 1 sells
Members Who Traded This Stock
1 trade events
| Date | Member | Stock | Type | Amount | Filed | Signal |
|---|---|---|---|---|---|---|
| 2023-01-31 | FATEFate Therapeutics, Inc. | Sell | $1,001 - $15,000 | 1133d ago | — |
2023-01-31
Daniel Goldman
FATE
Amount
$1,001 - $15,000
Filed
1133d ago
Recent News
Powered by Polygon.io
Scalable Biotech Manufacturing Unlocks a $14B Market
Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
Breaking Barriers: How 2026’s Top Clinical Leaders Are Disrupting Chronic Disease Markets
Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy
Trade Timeline
Congressional activity, newest first
Daniel Goldman
2023-01-31 · Sale
$1,001 - $15,000